| Literature DB >> 28471529 |
Marina Trivisano1,2, Chiara Lucchi3,4, Cecilia Rustichelli5, Alessandra Terracciano6, Raffaella Cusmai1, Grazia Maria Ubertini7, Germana Giannone8, Enrico Silvio Bertini6, Federico Vigevano1, Jozef Gecz9,10, Giuseppe Biagini3,4, Nicola Specchio1.
Abstract
Patients affected by protocadherin 19 (PCDH19)-female limited epilepsy (PCDH19-FE) present a remarkable reduction in allopregnanolone blood levels. However, no information is available on other neuroactive steroids and the steroidogenic response to hormonal stimulation. For this reason, we evaluated allopregnanolone, pregnanolone, and pregnenolone sulfate by liquid chromatographic procedures coupled with electrospray tandem mass spectrometry in 12 unrelated patients and 15 age-matched controls. We also tested cortisol, estradiol, progesterone, and 17OH-progesterone using standard immunoassays. Apart from estradiol and progesterone, all the considered hormones were evaluated in basal condition and after stimulation with adrenocorticotropic hormone (ACTH). A generalized decrease in blood levels of almost all measured neuroactive steroids was found. When considering sexual development, cortisol and pregnenolone sulfate basal levels were significantly reduced in postpubertal girls affected by PCDH19-FE. Of interest, ACTH administration did not recover pregnenolone sulfate serum levels but restored cortisol to control levels. In prepubertal girls with PCDH19-FE, by challenging adrenal function with ACTH we disclosed defects in the production of cortisol, pregnenolone sulfate, and 17OH-progesterone, which were not apparent in basal condition. These findings point to multiple defects in peripheral steroidogenesis associated with and potentially relevant to PCDH19-FE. Some of these defects could be addressed by stimulating adrenocortical activity. Wiley Periodicals, Inc.Entities:
Keywords: Adrenocorticotropic hormone; Allopregnanolone; Cortisol; Female-limited epilepsy; PCDH19; Pregnenolone sulfate
Mesh:
Substances:
Year: 2017 PMID: 28471529 DOI: 10.1111/epi.13772
Source DB: PubMed Journal: Epilepsia ISSN: 0013-9580 Impact factor: 5.864